Evidence map›Paper›PMID 38769210›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2024

Salivary, lacrimal and nasal (SALANS) measure to assess side effects following radioactive iodine treatment: development, psychometric properties, and factor structure.

Jacqueline Jonklaas, Alaina L Carr, George Luta, Chenlu Yu, Roxanne E Jensen, Emma Reasner, Justin Winslow, Charlene C Kuo, Bruce J Davidson, Giuseppe Esposito and 3 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06980103 (Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06980103 narecruitingnot on this mapstarted 2025, after this paper: background citation

Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer: The Radiance Trial

TypeinterventionalSponsorGeorgetown UniversityRan2025 to 2029Enrolled408ConditionsThyroid CancerArmsDecision Aid, Usual Care
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jacqueline JonklaasDivision of Endocrinology, Department of Medicine, Georgetown University, Washington, DC, USA. jonklaaj@georgetown.edu.ORCID http://orcid.org/0000-0002-2238-2666
Alaina L CarrDepartment of Oncology, Lombardi Comprehensive Cancer Center, Cancer Prevention and Control Program, Georgetown University, Washington, DC, USA.ORCID http://orcid.org/0000-0002-9226-8439
George LutaDepartment of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC, USA.ORCID http://orcid.org/0000-0002-4035-7632
Chenlu YuDepartment of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC, USA.
Roxanne E JensenOutcomes Research Branch, National Cancer Institute, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4632-1091
Emma ReasnerDepartment of Human Science, Georgetown University, Washington, DC, USA.ORCID http://orcid.org/0009-0000-0495-167X
Justin WinslowDepartment of Biology, Georgetown University Human Science Georgetown University, Washington, DC, USA.ORCID http://orcid.org/0009-0000-5591-7447
Charlene C KuoDepartment of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, MD, USA.ORCID http://orcid.org/0000-0001-9059-3249
Bruce J DavidsonDepartment of Otolaryngology-Head and Neck Surgery, MedStar Georgetown University Hospital, Washington, DC, USA.
Giuseppe EspositoDivision of Nuclear Medicine, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0002-9326-2856
Gary BloomThyCa: Thyroid Cancer Survivors' Association, Inc., Olney, MD, USA.ORCID http://orcid.org/0009-0000-1016-6272
Samantha A Diamond-RossiDivision of Endocrinology, INOVA Schar Cancer Institute, INOVA Fairfax Hospital, Fairfax, VA, USA.ORCID http://orcid.org/0009-0003-2327-0513
Kristi D GravesDepartment of Oncology, Lombardi Comprehensive Cancer Center, Cancer Prevention and Control Program, Georgetown University, Washington, DC, USA.ORCID http://orcid.org/0000-0001-8808-1631

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI Louis M Weiner · 1990 to 2026
$71.5M
Capturing the Impact of Craniofacial Damage after Radioiodine TherapyR01DE025822 · NIDCR · GEORGETOWN UNIVERSITY · PI GRAVES, KRISTI D., JONKLAAS, JACQUELINE · 2016 to 2020
$1.3M
Training Program in Cancer Population Science (CaPS)T32CA261787 · NCI · GEORGETOWN UNIVERSITY · PI Lucile L. Adams-Campbell, Suzanne C. O'Neill · 2021 to 2026
$1.1M
Use of a decision aid to resolve uncertainty about radioactive iodine treatment in patients with intermediate-risk thyroid cancer: the Radiance trialUG3DE031248 · NIDCR · GEORGETOWN UNIVERSITY · PI GRAVES, KRISTI D., JONKLAAS, JACQUELINE · 2022 to 2023
$653k
The development of a technology-based information support intervention (iSupport) among patients with differentiated thyroid cancer post radioactive iodine therapyK99CA277588 · NCI · GEORGETOWN UNIVERSITY · PI CARR, ALAINA L · 2023 to 2024
$255k
NCI NIH HHS K99 CA277588NCI NIH HHS K99CA277588NCI NIH HHS P30 CA051008NCI NIH HHS T32 CA261787NCI NIH HHS T32CA261787NIDCR NIH HHS R01 DE025822NIDCR NIH HHS R01DE025822NIDCR NIH HHS UG3 DE031248
6 · The paper itself

Abstract

purposeThis study aimed to develop and psychometrically evaluate a patient-reported outcome measure (PROM), SAlivary, LAcrimal, NaSal (SALANS), to document patients' symptoms after radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC).

methodsWe generated and iteratively revised SALANS items based on expert input, focus group discussions and feedback from cognitive testing (n = 17). We administered an initial SALANS measure with 39 items to patients diagnosed with DTC in the past two years (n = 105). Exploratory factor analysis (EFA) examined the factor structure of the SALANS items. We assessed the consistency reliability and related the total and subscale scores of the final SALANS to existing PROMs to assess validity.

resultsThe final SALANS consisted of 33 items and six subscales (sialadenitis, taste, xerostomia, dry eyes, epiphora, and nasal) with six factors extracted by EFA. The six subscales demonstrated good internal reliability (α range = 0.87-0.92). The SALANS total score showed good convergent validity with the Xerostomia Inventory (r = 0.86) and good discriminant validity with a measure of spirituality (r =  - 0.05). The mean SALANS total score was significantly higher (d = 0.5, p < 0.04) among patients who had RAI compared to those who did not have RAI.

conclusionPreliminary evidence suggests that SALANS is a novel and reliable PROM to assess the type and frequency all symptoms experienced after RAI treatment for DTC. Future work is needed to further validate and develop the scale.

Indexed as

Iodine RadioisotopesPatient Reported Outcome MeasuresPsychometricsThyroid NeoplasmsAdultAgedFactor Analysis, StatisticalFemaleHumansMaleMiddle AgedQuality of LifeReproducibility of ResultsSurveys and QuestionnairesXerostomiaIodine RadioisotopesDrug-related side effects and adverse reactionsExploratory factor analysisIodine radioisotopesThyroid neoplasmsXerostomia

Identifiers

PMID38769210
PMCPMC12212748

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.